Retatrutide (GLP-3)

What Is Retatrutide?

Retatrutide (LY3437943) is a synthetic peptide composed of 39 amino acids, engineered with a C20 fatty diacid moiety that extends its half-life to approximately six days and supports once-weekly administration in research settings. Originally developed by Eli Lilly, it belongs to a new generation of nutrient-stimulated hormone-based research compounds and has drawn substantial scientific attention for its unique triple-agonist activity.

Unlike single- or dual-receptor peptides, Retatrutide simultaneously targets three key metabolic receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). This combined activity makes it one of the most extensively studied triagonist peptides in preclinical and clinical metabolic research (Coskun et al., 2022).

Mechanism of Action

Retatrutide is studied for its balanced yet distinct activation of three G protein-coupled receptors that regulate energy balance, appetite, and glucose homeostasis. It demonstrates higher potency at the GIP receptor (EC50: 0.0643 nM) relative to the GLP-1 (EC50: 0.775 nM) and glucagon (EC50: 5.79 nM) receptors (Li et al., 2024).

Through GLP-1R activation, Retatrutide is associated with enhanced glucose-stimulated insulin secretion, delayed gastric emptying, and increased satiety. GIPR agonism supports glucose-dependent insulin release and lipid metabolism, while GCGR activation is linked to increased energy expenditure, hepatic lipolysis, and thermogenesis — processes that together distinguish it from earlier incretin-based research compounds such as semaglutide and tirzepatide.

Key Areas of Research

Body Weight Regulation

Phase 2 clinical studies report dose-dependent reductions in body weight of up to 17.5% at 24 weeks and 24.2% at 48 weeks in adults with obesity, with retatrutide showing superior efficacy compared to dual and single receptor agonists (Jastreboff et al., 2023).

Glycemic Control & Type 2 Diabetes

Research in participants with type 2 diabetes has shown robust reductions in HbA1c and fasting plasma glucose levels, alongside meaningful improvements in insulin sensitivity (Rosenstock et al., 2023).

Hepatic Fat & MASLD

A phase 2a trial in metabolic dysfunction-associated steatotic liver disease reported up to 82% reduction in liver fat content, positioning Retatrutide as a leading candidate in hepatic research (Sanyal et al., 2024).

Cardiometabolic Markers

Studies indicate improvements in lipid profiles, including approximately 20% reductions in LDL cholesterol, potentially linked to glucagon-mediated PCSK9 degradation (Jastreboff et al., 2023).

Energy Expenditure & Metabolism

Preclinical and mechanistic research highlights Retatrutide's role in increasing thermogenesis and lipid mobilization through glucagon receptor activity — a mechanism not present in GLP-1-only compounds.

Research Use Only

Retatrutide supplied by Peptidos.eu is intended exclusively for laboratory and scientific research. It is not approved for human or animal consumption and must not be used as a medicine or diagnostic tool.

Disclaimer

The products offered by peptidos.eu are intended exclusively for research and laboratory use and are sold only to qualified professionals, institutions, or authorized entities. These products are not intended for human or veterinary consumption, nor for any application involving living organisms, including — but not limited to — diagnostic, therapeutic, or recreational purposes.

By Making a Purchase, the Customer Declares that:

• They are a qualified professional or entity, possessing the necessary competence, training, and facilities for the safe handling of chemical reagents;

• They will use the product in full compliance with all applicable local, national, and European Union laws and regulations;

• They will adopt appropriate safety measures during all stages of handling, storage, and disposal.

Prohibited Uses

• The product must not be used as an Active Pharmaceutical Ingredient (API) in the manufacturing or preparation of medicines intended for humans or animals;

• Any direct administration or use on humans or animals is strictly prohibited;

• Peptidos.eu does not endorse or permit the use of its products for the production, testing, or development of illegal substances.

Liability

• The purchaser assumes full responsibility for the handling, storage, and use of the product in safe conditions and in compliance with the law.

• Peptidos.eu shall not be held liable for any direct or indirect damages arising from improper use, incorrect storage, or unauthorized use of the product.

• Peptidos.eu reserves the right to refuse the sale to any individual or entity suspected of improper use of its products.

• In case of doubts regarding the safe and lawful use of the product, it is recommended to consult a qualified professional experienced in laboratory research.

Regulatory Compliance

Peptidos.eu does not claim or imply that its products are approved by the European Medicines Agency (EMA), the Food and Drug Administration (FDA), or any other regulatory authority. All information provided is for informational and scientific purposes only. These products are not intended to diagnose, treat, cure, or prevent any disease.